- Home
- RRC vs ROIV Comparison
RRC vs ROIV Comparison
Compare RRC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRC
- ROIV
- Stock Information
- Founded
- RRC 1976
- ROIV 2014
- Country
- RRC United States
- ROIV United Kingdom
- Employees
- RRC N/A
- ROIV N/A
- Industry
- RRC Oil & Gas Production
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- RRC Energy
- ROIV Health Care
- Exchange
- RRC Nasdaq
- ROIV Nasdaq
- Market Cap
- RRC 8.0B
- ROIV 8.4B
- IPO Year
- RRC N/A
- ROIV N/A
- Fundamental
- Price
- RRC $39.00
- ROIV $10.99
- Analyst Decision
- RRC Hold
- ROIV Buy
- Analyst Count
- RRC 18
- ROIV 4
- Target Price
- RRC $42.00
- ROIV $17.50
- AVG Volume (30 Days)
- RRC 2.9M
- ROIV 6.2M
- Earning Date
- RRC 04-22-2025
- ROIV 05-29-2025
- Dividend Yield
- RRC 0.92%
- ROIV N/A
- EPS Growth
- RRC N/A
- ROIV N/A
- EPS
- RRC 1.11
- ROIV N/A
- Revenue
- RRC $2,610,836,000.00
- ROIV $122,585,000.00
- Revenue This Year
- RRC $34.77
- ROIV N/A
- Revenue Next Year
- RRC $8.93
- ROIV N/A
- P/E Ratio
- RRC $35.01
- ROIV N/A
- Revenue Growth
- RRC 12.00
- ROIV 140.04
- 52 Week Low
- RRC $27.29
- ROIV $8.73
- 52 Week High
- RRC $41.95
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- RRC 66.15
- ROIV 53.31
- Support Level
- RRC $33.42
- ROIV $11.02
- Resistance Level
- RRC $35.31
- ROIV $11.77
- Average True Range (ATR)
- RRC 1.06
- ROIV 0.34
- MACD
- RRC 0.63
- ROIV -0.03
- Stochastic Oscillator
- RRC 90.33
- ROIV 34.73
About RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.